Onesource Specialty Pharma Limited has informed the Exchange regarding Appointment ofMr. Jeffrey Wong as the Chief Business Officer of the company w.e.f. July 07, 2025.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma Limited (formerly Stelis Biopharma) has appointed Mr. Jeffrey Wong as its Chief Business Officer, effective July 7, 2025. Wong brings over 30 years of biopharmaceutical experience, having most recently served as Head of Biologics at Syngene International. He has also held senior leadership roles at Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, and Sartorius Stedim Biotech. His expertise covers bioprocess products, CDMO services, and commercial strategy across mammalian, microbial, and cell and gene therapy platforms. The appointment was disclosed under SEBI Regulation 30 as a senior managerial personnel change, with no fixed term specified.
Hiring a senior commercial leader with deep global CDMO and biologics experience suggests Onesource is focused on scaling its business development and client partnerships. This is a routine senior management announcement and is unlikely to trigger any immediate stock price reaction, but it strengthens the company's commercial leadership bench.